Predict your next investment

Venture Capital
shangbaycapital.com

See what CB Insights has to offer

Investments

28

Portfolio Exits

3

Funds

2

About Shangbay Capital

ShangBay Capital is a venture capital company bringing both U.S. and Chinese investors access to investments mainly in the U.S. medical devices technology, as well as biotech, and mobile healthcare sectors through early stage venture equity participation.

Shangbay Capital Headquarter Location

530 Lytton Ave 2nd Floor

Palo Alto, California, 94303,

United States

650-575-7716

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Shangbay Capital News

Robert Kamen, Ph.D., Joins ShangBay Capital as a Senior Advisor

Nov 3, 2021

Robert Kamen, Ph.D., Joins ShangBay Capital as a Senior Advisor PALO ALTO, Calif., November 2, 2021-- ShangBay Capital, a venture capital firm focused on investing in early-stage healthcare companies, today announced that Robert Kamen, Ph.D., has joined its advisory team as a Senior Advisor. The venture capital firm is one of the most prolific investors in medtech. Dr. Kamen will provide tremendous value in the biotech and biopharma investment fields for potential new companies. ShangBay Capital’s team has a proven track record of identifying, financing, and building various healthcare companies over the last several years. The team brings deep operational experience from more than 100 years of combined industry experience to help entrepreneurs build lasting companies. “Bob will bring significant value from his more than 35 years of experience of launching and operating successful biotech and pharmaceutical companies,” said William Dai, Founding Managing Partner. “His in-depth experience will help ShangBay continue to build a great portfolio of disruptive biotechnologies to improve patient outcome.” Dr. Kamen is also a venture partner at Third Rock Ventures. Prior to that, he served as an executive-in-residence at Oxford Bioscience Partners. Dr. Kamen’s career began as Senior VP Scientific Affairs at Genetics Institute, Inc., a pioneering biopharmaceutical firm that was acquired by Wyeth. He previously served as president of Abbott Bioresearch Center, where he oversaw the discovery and production of Humira, the first fully human antibody to achieve marketing approval in the U.S. and Europe and was a member of the Abbott Pharmaceuticals Executive Management Committee. He also was the president of the BASF Bioresearch Corp. until it was acquired by Abbott Laboratories in 2001. Dr. Kamen is a co-founder of BioAssets Development Corporation, a biotherapeutics company focusing on spinal diseases, that was acquired by Cephalon. Dr. Kamen serves as a director of Jounce Therapeutics, Harbour Biomed, and EpimAb Biotherapeutics. He previously served as a director at Neon Therapeutics, Harbour Antibodies, Lycera, Opsonic Therapeutics, and Anchor Therapeutics and was a member of the GlaxoSmithKline Biopharma Investment Board. Dr. Kamen received his undergraduate degree in biophysics from Amherst College (summa cum laude) and his Ph.D. in biochemistry and molecular biology from Harvard University. About ShangBay Capital Founded in 2015, ShangBay Capital is a Silicon Valley-based venture capital company that brings investors access to best-in-class investments in U.S. medical device technologies, biotechnology, biopharmaceutical, and digital health sectors through early-stage venture equity participation. Contact:

Shangbay Capital Investments

28 Investments

Shangbay Capital has made 28 investments. Their latest investment was in yoR Labs as part of their Unattributed VC on November 11, 2021.

CBI Logo

Shangbay Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

11/3/2021

Unattributed VC

yoR Labs

$12.53M

Yes

Undisclosed Investors

2

10/20/2021

Series A - II

Contraline

$10.7M

Yes

1

9/3/2021

Series A

Laplace Interventional

$7.9M

Yes

Mayo Clinic Ventures, and Undisclosed Venture Investors

3

8/11/2021

Seed VC

Subscribe to see more

$99M

Subscribe to see more

10

7/27/2021

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/3/2021

10/20/2021

9/3/2021

8/11/2021

7/27/2021

Round

Unattributed VC

Series A - II

Series A

Seed VC

Series A

Company

yoR Labs

Contraline

Laplace Interventional

Subscribe to see more

Subscribe to see more

Amount

$12.53M

$10.7M

$7.9M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Undisclosed Investors

Mayo Clinic Ventures, and Undisclosed Venture Investors

Sources

2

1

3

10

10

Shangbay Capital Portfolio Exits

3 Portfolio Exits

Shangbay Capital has 3 portfolio exits. Their latest portfolio exit was Devoro Medical on September 21, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

9/21/2021

Acquired

$99M

2

2/5/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

12/12/2018

Acquired

Subscribe to see more

Subscribe to see more

10

Date

9/21/2021

2/5/2021

12/12/2018

Exit

Acquired

IPO

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

2

10

10

Shangbay Capital Fund History

2 Fund Histories

Shangbay Capital has 2 funds, including ShangBay Capital.

Closing Date

Fund

Fund Type

Status

Amount

Sources

8/10/2015

ShangBay Capital

Early-Stage Venture Capital

Closed

$5M

1

Shangbay Capital II

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

8/10/2015

Fund

ShangBay Capital

Shangbay Capital II

Fund Type

Early-Stage Venture Capital

Subscribe to see more

Status

Closed

Subscribe to see more

Amount

$5M

$99M

Sources

1

10

Shangbay Capital Team

2 Team Members

Shangbay Capital has 2 team members, including current Founder, Managing Partner, William Dai.

Name

Work History

Title

Status

William Dai

Founder, Managing Partner

Current

Chaucer Shen

Managing Partner

Current

Name

William Dai

Chaucer Shen

Work History

Title

Founder, Managing Partner

Managing Partner

Status

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.